[Responses of advanced esophageal cancer to chemotherapy and prognostic factors: a report of 138 cases].

Aina Liu(Qingdao University), Jinwan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiangru Zhang(Chinese Academy of Sciences), Dongmei Shi(Weifang University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaohui He(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruigang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College)
PubMed
April 1, 2008
Cited by 1

Related Papers

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
|The Lancet Respiratory Medicine|2022|235
Characterization of key aroma compounds in Gujinggong Chinese Baijiu by gas chromatography–olfactometry, quantitative measurements, and sensory evaluation
|Food Research International|2017|214